Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ.

Al-Jameel W, Gou X, Jin X, Zhang J, Wei Q, Ai J, Li H, Al-Bayati A, Platt-Higgins A, Pettitt A, Rudland PS, Ke Y.

Genes Cancer. 2019 May;10(3-4):80-96. doi: 10.18632/genesandcancer.192.

2.

The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.

Dakir EH, Pickard A, Srivastava K, McCrudden CM, Gross SR, Lloyd S, Zhang SD, Margariti A, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2018 Oct 9;9(79):34889-34910. doi: 10.18632/oncotarget.26175. eCollection 2018 Oct 9.

3.

S100P enhances the motility and invasion of human trophoblast cell lines.

Tabrizi MEA, Lancaster TL, Ismail TM, Georgiadou A, Ganguly A, Mistry JJ, Wang K, Rudland PS, Ahmad S, Gross SR.

Sci Rep. 2018 Jul 31;8(1):11488. doi: 10.1038/s41598-018-29852-2.

4.

T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes.

Zakaria R, Platt-Higgins A, Rathi N, Radon M, Das S, Das K, Bhojak M, Brodbelt A, Chavredakis E, Jenkinson MD, Rudland PS.

Cancer Res. 2018 Feb 1;78(3):610-616. doi: 10.1158/0008-5472.CAN-17-1720. Epub 2017 Dec 6.

5.

Activation of tissue plasminogen activator by metastasis-inducing S100P protein.

Clarke CJ, Gross SR, Ismail TM, Rudland PS, Al-Medhtiy M, Santangeli M, Barraclough R.

Biochem J. 2017 Sep 12;474(19):3227-3240. doi: 10.1042/BCJ20170578.

PMID:
28798096
6.

Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.

Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.

7.

Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.

Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA, Ke Y.

Oncotarget. 2017 May 9;8(19):31041-31056. doi: 10.18632/oncotarget.16055.

8.

S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.

Ismail TM, Bennett D, Platt-Higgins AM, Al-Medhity M, Barraclough R, Rudland PS.

Cancer Res. 2017 Feb 1;77(3):780-789. doi: 10.1158/0008-5472.CAN-16-1802. Epub 2016 Nov 10.

9.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

10.

Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response.

Zakaria R, Platt-Higgins A, Rathi N, Crooks D, Brodbelt A, Chavredakis E, Lawson D, Jenkinson MD, Rudland PS.

Br J Cancer. 2016 May 10;114(10):1101-8. doi: 10.1038/bjc.2016.103. Epub 2016 Apr 21.

11.

Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.

Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Al Fayi MS, Al-Jameel W, Rudland PS, Hussain SA, Ke Y.

Oncotarget. 2016 Feb 23;7(8):9322-39. doi: 10.18632/oncotarget.6975.

12.

Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.

PMID:
26088937
13.

The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer.

Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, Rudland PS, Foster CS, Ke Y.

Int J Oncol. 2014 Jan;44(1):265-75. doi: 10.3892/ijo.2013.2166. Epub 2013 Nov 5.

PMID:
24189640
14.

A novel cutaneous Fatty Acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells.

Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, Foster CS, Rudland PS, Ke Y.

Genes Cancer. 2013 Jul;4(7-8):297-314. doi: 10.1177/1947601913499155.

15.

Joining S100 proteins and migration: for better or for worse, in sickness and in health.

Gross SR, Sin CG, Barraclough R, Rudland PS.

Cell Mol Life Sci. 2014 May;71(9):1551-79. doi: 10.1007/s00018-013-1400-7. Epub 2013 Jun 30. Review.

PMID:
23811936
16.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
17.

Metastasis-promoting anterior gradient 2 protein has a dimeric thioredoxin fold structure and a role in cell adhesion.

Patel P, Clarke C, Barraclough DL, Jowitt TA, Rudland PS, Barraclough R, Lian LY.

J Mol Biol. 2013 Mar 11;425(5):929-43. doi: 10.1016/j.jmb.2012.12.009. Epub 2012 Dec 26.

18.

Asymmetric mode of Ca²⁺-S100A4 interaction with nonmuscle myosin IIA generates nanomolar affinity required for filament remodeling.

Elliott PR, Irvine AF, Jung HS, Tozawa K, Pastok MW, Picone R, Badyal SK, Basran J, Rudland PS, Barraclough R, Lian LY, Bagshaw CR, Kriajevska M, Barsukov IL.

Structure. 2012 Apr 4;20(4):654-66. doi: 10.1016/j.str.2012.02.002. Epub 2012 Apr 3.

19.

S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.

Du M, Wang G, Ismail TM, Gross S, Fernig DG, Barraclough R, Rudland PS.

J Biol Chem. 2012 May 4;287(19):15330-44. doi: 10.1074/jbc.M112.349787. Epub 2012 Mar 6.

20.

Aberrant expression of metastasis-inducing proteins in ectopic and matched eutopic endometrium of women with endometriosis: implications for the pathogenesis of endometriosis.

Hapangama DK, Raju RS, Valentijn AJ, Barraclough D, Hart A, Turner MA, Platt-Higgins A, Barraclough R, Rudland PS.

Hum Reprod. 2012 Feb;27(2):394-407. doi: 10.1093/humrep/der412. Epub 2011 Dec 6.

PMID:
22147918
21.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

22.

S100A4 downregulates filopodia formation through increased dynamic instability.

Goh Then Sin C, Hersch N, Rudland PS, Barraclough R, Hoffmann B, Gross SR.

Cell Adh Migr. 2011 Sep-Oct;5(5):439-47. doi: 10.4161/cam.5.5.17773.

23.

Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.

de Silva Rudland S, Platt-Higgins A, Winstanley JH, Jones NJ, Barraclough R, West C, Carroll J, Rudland PS.

Am J Pathol. 2011 Aug;179(2):1061-72. doi: 10.1016/j.ajpath.2011.04.022. Epub 2011 Jun 14.

24.
25.

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS.

Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10.

26.

Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, Winstanley JH, Barraclough DL, Barraclough R, West CR, Jones NJ.

Am J Pathol. 2010 Jun;176(6):2935-47. doi: 10.2353/ajpath.2010.090779. Epub 2010 Apr 2.

27.

Microarray analysis of suppression subtracted hybridisation libraries identifies genes associated with breast cancer progression.

Barraclough DL, Sewart S, Rudland PS, Shoker BS, Sibson DR, Barraclough R, Davies MP.

Cell Oncol. 2010;32(1-2):87-99. doi: 10.3233/CLO-2009-0499.

28.

Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer.

Edgell TA, Barraclough DL, Rajic A, Dhulia J, Lewis KJ, Armes JE, Barraclough R, Rudland PS, Rice GE, Autelitano DJ.

Clin Sci (Lond). 2010 Mar 30;118(12):717-25. doi: 10.1042/CS20090537. Erratum in: Clin Sci (Lond). 2010;119(6):263.

PMID:
20136634
29.

Self-association of calcium-binding protein S100A4 and metastasis.

Ismail TM, Zhang S, Fernig DG, Gross S, Martin-Fernandez ML, See V, Tozawa K, Tynan CJ, Wang G, Wilkinson MC, Rudland PS, Barraclough R.

J Biol Chem. 2010 Jan 8;285(2):914-22. doi: 10.1074/jbc.M109.010892. Epub 2009 Nov 16.

30.

The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients.

Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, West CR, Rudland PS.

Am J Pathol. 2009 Nov;175(5):1848-57. doi: 10.2353/ajpath.2009.090246. Epub 2009 Oct 15.

31.

Molecular analysis of a collection of clinical specimens stored at 4 degrees C as an alternative to snap-freezing.

Sewart S, Barraclough R, Rudland PS, West CR, Barraclough DL.

Int J Oncol. 2009 Aug;35(2):381-6.

PMID:
19578753
32.

Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells.

Kurisetty VV, Johnston PG, Rudland PS, El-Tanani MK.

BMC Res Notes. 2009 Feb 3;2:15. doi: 10.1186/1756-0500-2-15.

33.

RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin.

Kurisetty VV, Johnston PG, Johnston N, Erwin P, Crowe P, Fernig DG, Campbell FC, Anderson IP, Rudland PS, El-Tanani MK.

Oncogene. 2008 Dec 4;27(57):7139-49. doi: 10.1038/onc.2008.325. Epub 2008 Sep 15.

PMID:
18794800
34.

The basic C-terminal amino acids of calcium-binding protein S100A4 promote metastasis.

Ismail TM, Fernig DG, Rudland PS, Terry CJ, Wang G, Barraclough R.

Carcinogenesis. 2008 Dec;29(12):2259-66. doi: 10.1093/carcin/bgn217. Epub 2008 Sep 10.

PMID:
18784356
35.

ATP depletion induces translocation of STIM1 to puncta and formation of STIM1-ORAI1 clusters: translocation and re-translocation of STIM1 does not require ATP.

Chvanov M, Walsh CM, Haynes LP, Voronina SG, Lur G, Gerasimenko OV, Barraclough R, Rudland PS, Petersen OH, Burgoyne RD, Tepikin AV.

Pflugers Arch. 2008 Nov;457(2):505-17. doi: 10.1007/s00424-008-0529-y. Epub 2008 Jun 10.

36.

Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.

Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough R, Rudland PS, Sibson DR.

Int J Cancer. 2008 Jul 1;123(1):85-8. doi: 10.1002/ijc.23479.

37.

Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients.

Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y.

Prostate Cancer Prostatic Dis. 2007;10(3):293-300. Epub 2007 Apr 24.

PMID:
17457305
38.

The regulation and role of osteopontin in malignant transformation and cancer.

El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS.

Cytokine Growth Factor Rev. 2006 Dec;17(6):463-74. Epub 2006 Nov 17. Review.

PMID:
17113338
39.

BRCA1 suppresses osteopontin-mediated breast cancer.

El-Tanani MK, Campbell FC, Crowe P, Erwin P, Harkin DP, Pharoah P, Ponder B, Rudland PS.

J Biol Chem. 2006 Sep 8;281(36):26587-601. Epub 2006 Jun 28.

40.

Differential involvement of ERK1-2 and p38MAPK activation on Swiss 3T3 cell proliferation induced by prostaglandin F2alpha.

Dekanty A, Giulianelli S, Coso OA, Rudland PS, Jimenez de Asua L.

FEBS Lett. 2006 May 1;580(10):2512-6. Epub 2006 Apr 7.

41.

Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients.

Innes HE, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS.

Br J Cancer. 2006 Apr 10;94(7):1057-65.

42.

Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.

Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS.

Cancer Res. 2006 Jan 15;66(2):1199-207.

43.

Leukemia inhibitory factor induces DNA synthesis in Swiss mouse 3T3 cells independently of cyclin D1 expression through a mechanism involving MEK/ERK1/2 activation.

Dekanty A, Sauane M, Cadenas B, Coluccio F, Barrio M, Casala J, Paciencia M, Rogers F, Coso OA, Piwien-Pilipuk G, Rudland PS, de Asúa LJ.

J Biol Chem. 2006 Mar 10;281(10):6136-43. Epub 2005 Nov 15.

44.

Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas.

Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R.

Cancer Res. 2005 May 1;65(9):3796-805.

45.

The C-terminal region of S100A4 is important for its metastasis-inducing properties.

Zhang S, Wang G, Liu D, Bao Z, Fernig DG, Rudland PS, Barraclough R.

Oncogene. 2005 Jun 23;24(27):4401-11.

PMID:
15856021
46.

Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes.

Wang G, Zhang S, Fernig DG, Martin-Fernandez M, Rudland PS, Barraclough R.

Oncogene. 2005 Feb 17;24(8):1445-54.

PMID:
15608682
47.

Interaction of metastasis-inducing S100A4 protein in vivo by fluorescence lifetime imaging microscopy.

Zhang S, Wang G, Fernig DG, Rudland PS, Webb SE, Barraclough R, Martin-Fernandez M.

Eur Biophys J. 2005 Feb;34(1):19-27. Epub 2004 Aug 3.

PMID:
15289939
48.

Heterodimeric interaction and interfaces of S100A1 and S100P.

Wang G, Zhang S, Fernig DG, Spiller D, Martin-Fernandez M, Zhang H, Ding Y, Rao Z, Rudland PS, Barraclough R.

Biochem J. 2004 Aug 15;382(Pt 1):375-83.

49.
50.

Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription.

El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC.

J Biol Chem. 2004 May 14;279(20):20794-806. Epub 2004 Feb 27.

Supplemental Content

Loading ...
Support Center